Wedbush Issues Negative Estimate for RARE Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush dropped their Q1 2025 earnings estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of ($1.09) per share for the quarter, down from their prior estimate of ($1.06). Wedbush currently has a “Neutral” rating and a $48.00 price target on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.78) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.81) EPS, FY2028 earnings at $1.91 EPS and FY2029 earnings at $3.20 EPS.

Several other equities research analysts have also weighed in on RARE. HC Wainwright reissued a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Piper Sandler dropped their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday, March 17th. Wells Fargo & Company lifted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Canaccord Genuity Group increased their target price on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $92.79.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $35.69 on Friday. Ultragenyx Pharmaceutical has a 1 year low of $29.59 and a 1 year high of $60.37. The business has a fifty day simple moving average of $38.41 and a two-hundred day simple moving average of $44.26. The company has a market capitalization of $3.35 billion, a P/E ratio of -5.63 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million.

Insider Activity

In other news, CEO Emil D. Kakkis sold 25,000 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the transaction, the chief executive officer now owns 2,158,985 shares of the company’s stock, valued at $91,713,682.80. This represents a 1.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas Richard Kassberg sold 6,028 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the sale, the executive vice president now directly owns 265,238 shares of the company’s stock, valued at $11,166,519.80. This represents a 2.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 124,643 shares of company stock worth $5,256,268. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently modified their holdings of the company. Norges Bank bought a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $40,463,000. Vestal Point Capital LP boosted its stake in shares of Ultragenyx Pharmaceutical by 100.0% in the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $63,105,000 after purchasing an additional 750,000 shares in the last quarter. Deep Track Capital LP bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $27,493,000. Pictet Asset Management Holding SA raised its position in Ultragenyx Pharmaceutical by 125.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company’s stock worth $49,375,000 after purchasing an additional 653,088 shares during the period. Finally, Point72 Asset Management L.P. lifted its stake in Ultragenyx Pharmaceutical by 81.0% in the fourth quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company’s stock worth $49,764,000 after purchasing an additional 529,217 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.